Zomedica Corp (AMEX: ZOM) closed the day trading at $0.12 down -1.61% from the previous closing price of $0.12. In other words, the price has decreased by -$0.0020 from its previous closing price. On the day, 3165060 shares were traded.
Ratios:
For a better understanding of ZOM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 93.78. For the most recent quarter (mrq), Quick Ratio is recorded 16.57 and its Current Ratio is at 17.12. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Dawson James on January 06, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 when POWERS JOHNNY D bought 100,000 shares for $0.17 per share. The transaction valued at 16,500 led to the insider holds 1,950 shares of the business.
HEATON LARRY C II bought 100,000 shares of ZOM for $16,600 on Nov 17. The CEO now owns 200,000 shares after completing the transaction at $0.17 per share. On Nov 17, another insider, POWERS JOHNNY D, who serves as the Director of the company, bought 100,000 shares for $0.17 each. As a result, the insider paid 16,600 and bolstered with 1,850,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZOM now has a Market Capitalization of 120.04M and an Enterprise Value of 15.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.00 while its Price-to-Book (P/B) ratio in mrq is 0.46. Its current Enterprise Value per Revenue stands at 0.65 whereas that against EBITDA is -1.31.
Stock Price History:
Over the past 52 weeks, ZOM has reached a high of $0.27, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 0.1566, while the 200-Day Moving Average is calculated to be 0.1800.
Shares Statistics:
Over the past 3-months, ZOM traded about 5.46M shares per day on average, while over the past 10 days, ZOM traded about 5.36M shares per day. A total of 979.95M shares are outstanding, with a floating share count of 964.36M. Insiders hold about 1.59% of the company’s shares, while institutions hold 8.88% stake in the company. Shares short for ZOM as of Jan 31, 2024 were 55.43M with a Short Ratio of 10.16, compared to 53.46M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.66% and a Short% of Float of 5.75%.
Earnings Estimates
Current recommendations for the stock of the company come from 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.01. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.02 and -$0.02 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.01, with 1 analysts recommending between -$0.01 and -$0.01.
Revenue Estimates
1 analysts predict $7M in revenue for the current quarter. It ranges from a high estimate of $7M to a low estimate of $7M. As of the current estimate, Zomedica Corp’s year-ago sales were $6.16M, an estimated increase of 13.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $8.18M, an increase of 49.20% over than the figure of $13.70% in the same quarter last year. There is a high estimate of $8.18M for the next quarter, whereas the lowest estimate is $8.18M.
A total of 1 analysts have provided revenue estimates for ZOM’s current fiscal year. The highest revenue estimate was $24.85M, while the lowest revenue estimate was $24.85M, resulting in an average revenue estimate of $24.85M. In the same quarter a year ago, actual revenue was $18.93M, up 31.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $34.1M in the next fiscal year. The high estimate is $34.1M and the low estimate is $34.1M. The average revenue growth estimate for next year is up 37.20% from the average revenue estimate for this year.
